Founder of Clovis Oncology, Inc., Gritstone bio, Inc. and Revitope Oncology, Inc., Andrew R. Allen is an entrepreneur who presently occupies the position of Executive Chairman of Revitope Oncology, Inc. and President, Chief Executive Officer & Director at Gritstone bio, Inc.

He is also on the board of Sierra Oncology, Inc., Verge Analytics, Inc. and TCR2 Therapeutics, Inc. and Member of The Royal College of Physicians.

In the past Andrew R. Allen occupied the position of Chief Medical Officer & EVP-Clinical Development at Clovis Oncology, Inc., Head-Global Project at Abbott Laboratories, Principal at McKinsey & Co., Inc., Chief Medical Officer & Executive VP-Clinical at Pharmion Corp. and Vice President-Oncology Drug Development at Chiron Corp.

Andrew R. Allen received a doctorate from Imperial College London and an undergraduate degree from the University of Oxford.